These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1642659)

  • 1. Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosis.
    Takemura H; Suzuki H; Yoshizaki K; Ogata A; Yuhara T; Akama T; Yamane K; Kashiwagi H
    Arthritis Rheum; 1992 Aug; 35(8):940-3. PubMed ID: 1642659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis.
    Chizzolini C; Raschi E; Rezzonico R; Testoni C; Mallone R; Gabrielli A; Facchini A; Del Papa N; Borghi MO; Dayer JM; Meroni PL
    Arthritis Rheum; 2002 Jun; 46(6):1602-13. PubMed ID: 12115192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-IL-1 alpha autoantibodies in patients with rheumatic diseases and in healthy subjects.
    Suzuki H; Ayabe T; Kamimura J; Kashiwagi H
    Clin Exp Immunol; 1991 Sep; 85(3):407-12. PubMed ID: 1893621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis.
    Suzuki H; Takemura H; Yoshizaki K; Koishihara Y; Ohsugi Y; Okano A; Akiyama Y; Tojo T; Kishimoto T; Kashiwagi H
    J Immunol; 1994 Jan; 152(2):935-42. PubMed ID: 8283060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies against calpastatin in sera from patients with systemic sclerosis.
    Sato S; Hasegawa M; Nagaoka T; Takamatsu Y; Yazawa N; Ihn H; Kikuchi K; Takehara K
    J Rheumatol; 1998 Nov; 25(11):2135-9. PubMed ID: 9818655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibodies from Patients with Scleroderma Renal Crisis Promote PAR-1 Receptor Activation and IL-6 Production in Endothelial Cells.
    Simon M; Lücht C; Hosp I; Zhao H; Wu D; Heidecke H; Witowski J; Budde K; Riemekasten G; Catar R
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.
    Jimenez-Boj E; Kedersha N; Tohidast-Akrad M; Karlhofer FM; Stummvoll G; Zimmermann C; Ulrich W; Guiducci S; Hoefler E; Aringer M; Schett G; Matucci-Cerinic M; Smolen JS; Steiner G
    Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders.
    Reitamo S; Remitz A; Varga J; Ceska M; Effenberger F; Jimenez S; Uitto J
    Arch Dermatol; 1993 Feb; 129(2):189-93. PubMed ID: 8434976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.
    Russo K; Hoch S; Dima C; Varga J; Teodorescu M
    J Rheumatol; 2000 Jan; 27(1):142-8. PubMed ID: 10648030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies.
    Cavazzana I; Fredi M; Taraborelli M; Quinzanini M; Tincani A; Franceschini F
    Clin Exp Rheumatol; 2013; 31(2 Suppl 76):118-21. PubMed ID: 23910615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls.
    Schmeling H; Mahler M; Levy DM; Moore K; Stevens AM; Wick J; McMillan JD; Horneff G; Assassi S; Charles J; Salazar G; Mayes MD; Silverman ED; Klien-Gitelman M; Lee T; Brunner HI; Reed AM; Fritzler MJ
    J Rheumatol; 2015 Dec; 42(12):2419-26. PubMed ID: 26472409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epitope Specificity Determines Pathogenicity and Detectability of Anti-Platelet-Derived Growth Factor Receptor α Autoantibodies in Systemic Sclerosis.
    Moroncini G; Grieco A; Nacci G; Paolini C; Tonnini C; Pozniak KN; Cuccioloni M; Mozzicafreddo M; Svegliati S; Angeletti M; Kazlauskas A; Avvedimento EV; Funaro A; Gabrielli A
    Arthritis Rheumatol; 2015 Jul; 67(7):1891-903. PubMed ID: 25808833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features of anti-chromo antibodies associated with anti-centromere antibodies.
    Iwai T; Muro Y; Sugimoto K; Matsumoto Y; Ohashi M
    Clin Exp Immunol; 1996 Aug; 105(2):285-90. PubMed ID: 8706335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts.
    Raschi E; Chighizola CB; Cesana L; Privitera D; Ingegnoli F; Mastaglio C; Meroni PL; Borghi MO
    Arthritis Res Ther; 2018 Aug; 20(1):187. PubMed ID: 30157947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
    Hénault J; Tremblay M; Clément I; Raymond Y; Senécal JL
    Arthritis Rheum; 2004 Oct; 50(10):3265-74. PubMed ID: 15476238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and serological heterogeneity in patients with anticentromere antibodies.
    Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
    J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.
    Hamaguchi Y
    J Dermatol; 2010 Jan; 37(1):42-53. PubMed ID: 20175839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis.
    Kill A; Tabeling C; Undeutsch R; Kühl AA; Günther J; Radic M; Becker MO; Heidecke H; Worm M; Witzenrath M; Burmester GR; Dragun D; Riemekasten G
    Arthritis Res Ther; 2014 Jan; 16(1):R29. PubMed ID: 24472528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies in systemic sclerosis.
    Mehra S; Walker J; Patterson K; Fritzler MJ
    Autoimmun Rev; 2013 Jan; 12(3):340-54. PubMed ID: 22743034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis.
    Terras S; Hartenstein H; Höxtermann S; Gambichler T; Kreuter A
    Int J Dermatol; 2016 Aug; 55(8):882-5. PubMed ID: 26499848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.